A tech-bio startup leveraging antibody big data and AI to tackle the challenges of drug discovery: identifying unresolved diseases and undiscovered target molecules. Breaking through the barriers of bio-data to pioneer new therapies.
[画像: https://prtimes.jp/i/104790/7/resize/d104790-7-89c8694c4d468e84072e-1.png ] 公開したデータセットをダウンロードできるWebサイト（https://avida-hil6.cognanous.com/） [表: https://prtimes.jp/d...
本事業は、8月9日の大阪府知事定例記者会見において発表された通り、令和５年度創薬シーズ研究開発費補助金として採択されました。事業名称は「新規がんマーカーを標的とするVHH創薬の高速プラットフォーム戦略（...
[画像1: https://prtimes.jp/i/104790/5/resize/d104790-5-7853acf9474c8fae17f8-3.jpg ] Fig. 1. TNBC89バイオマーカー(赤) が、エストロゲン受容体(緑)の発現が低い浸潤性乳管癌を染めている。 [画像2: http...
[画像: https://prtimes.jp/i/104790/2/resize/d104790-2-1151b0e11903c76a6885-0.jpg ] 京都のバイオラボでのバイオマンとエンジニアの作戦会議風景   1. 背景 新型コロナウイルス感染症（COVID-1...
A startup advancing thin-film, flexible perovskite solar cells from material development to module production based on Kyoto University research, providing the “Anywhere Power®” solution that enables high power generation not only on sunny days but also under cloudy skies and indoor lighting.
A femtech startup that develops period management apps and corporate health management support services, leveraging women's health data to simultaneously advance physical and mental care while addressing societal challenges.
Our company is an incubation firm specializing in medical devices, providing software development support from the concept stage through design transfer. In addition to IEC 62304–compliant development, we have strong capabilities in AI and 3D rendering technologies. Leveraging the technical expertise cultivated through joint development with major medical device manufacturers, we are able to deliver high-quality development at low cost and within short timeframes. We also offer regulatory consulting based on our knowledge of compliance, supporting a wide range of clients from startups to large enterprises.
AMI Inc. is a research and development–driven startup aiming to advance the development of AI-powered medical devices and the social implementation of telemedicine. Guided by our mission to "achieve a society where optimal medical care is accessible to everyone, everywhere, at any time," AMI is working toward the real-world deployment of the Super Stethoscope. The Super Stethoscope is a collective term encompassing hardware (Cardio-EGG), software (cloud-based diagnostic platform), technology (AI and Software as a Medical Device [SaMD]), and knowledge, among other components.
